Prostate‐specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma

Abstract

Prostate‐specific membrane antigen (PSMA) is a type II transmembrane glycoprotein encoded by the folate hydrolase 1 (FOLH1) gene. The enzyme is overexpressed in prostate cancer cells.1 A recent systematic review showed 68Ga‐labelled PSMA–positron emission tomography (PET) as having a sensitivity of 66% and specificity of 99% for primary lymph node metastases in high‐risk prostate cancer patients.2 PSMA‐PET is also positive in renal cell carcinoma, hepatocellular carcinoma, non‐small cell lung cancer, squamous cell (lung and other), gynaecological and colorectal malignancies.3-7